VolitionRX Ltd (AMEX: VNRX)’s stock price has gone decline by -9.00% in comparison to its previous close of $0.74, however, the company has experienced a -19.61% decrease in its stock price over the last five trading days. prnewswire.com reported 2025-06-12 that Peer Reviewed Clinical Study for H3.1 Biomarker Published in Critical Care HENDERSON, Nev., June 12, 2025 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, today announced the publication of a new clinical manuscript suggesting that the Nu.Q® H3.1 biomarker has the potential to inform clinical care in critically-ill Intensive Care Unit (ICU) patients in the assessment of sepsis, organ failure and subphenotypes.
Is It Worth Investing in VolitionRX Ltd (AMEX: VNRX) Right Now?
Additionally, the 36-month beta value for VNRX is 1.27. There are mixed opinions on the stock, with 3 analysts rating it as a “buy”, 2 rating it as “overweight”, 1 rating it as “hold”, and 0 rating it as “sell”.
The public float for VNRX is 76.14M and currently, short sellers hold a 0.24% ratio of that float. The average trading volume of VNRX on July 08, 2025 was 295.19K shares.
VNRX’s Market Performance
VNRX’s stock has seen a -19.61% decrease for the week, with a 18.06% rise in the past month and a 20.77% gain in the past quarter. The volatility ratio for the week is 10.81%, and the volatility levels for the past 30 days are at 13.61% for VolitionRX Ltd The simple moving average for the past 20 days is -5.25% for VNRX’s stock, with a 10.45% simple moving average for the past 200 days.
Analysts’ Opinion of VNRX
Many brokerage firms have already submitted their reports for VNRX stocks, with H.C. Wainwright repeating the rating for VNRX by listing it as a “Buy”. The predicted price for VNRX in the upcoming period, according to H.C. Wainwright is $2.50 based on the research report published on April 08, 2025 of the current year 2025.
Cantor Fitzgerald gave a rating of “Overweight” to VNRX, setting the target price at $8 in the report published on March 10th of the previous year.
VNRX Trading at 15.66% from the 50-Day Moving Average
After a stumble in the market that brought VNRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.36% of loss for the given period.
Volatility was left at 13.61%, however, over the last 30 days, the volatility rate increased by 10.81%, as shares surge +16.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +40.29% upper at present.
During the last 5 trading sessions, VNRX fell by -19.61%, which changed the moving average for the period of 200-days by -2.66% in comparison to the 20-day moving average, which settled at $0.7107. In addition, VolitionRX Ltd saw 6.89% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VNRX starting from Reynolds Cameron John, who purchase 12,500 shares at the price of $0.59 back on Jun 12 ’25. After this action, Reynolds Cameron John now owns 2,331,722 shares of VolitionRX Ltd, valued at $7,372 using the latest closing price.
Innes Guy Archibald, the Director of VolitionRX Ltd, purchase 20,000 shares at $0.54 during a trade that took place back on Jun 03 ’25, which means that Innes Guy Archibald is holding 888,689 shares at $10,772 based on the most recent closing price.
Stock Fundamentals for VNRX
Current profitability levels for the company are sitting at:
- -14.25% for the present operating margin
- 0.32% for the gross margin
The net margin for VolitionRX Ltd stands at -18.36%. The total capital return value is set at -75.48%.
Based on VolitionRX Ltd (VNRX), the company’s capital structure generated -0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -11.9. The debt to equity ratio resting at -0.09. The interest coverage ratio of the stock is -111.98.
Currently, EBITDA for the company is -25.62 million with net debt to EBITDA at 0.04. When we switch over and look at the enterprise to sales, we see a ratio of 52.44. The receivables turnover for the company is 6.97for trailing twelve months and the total asset turnover is 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.40.
Conclusion
In conclusion, VolitionRX Ltd (VNRX) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
